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Abstract
There is some evidence that antipsychotic medication (Quetiapine) is somewhat ef‐
ficient in reducing anxiety in schizophrenic patients.
This study compared the efficacy of Olanzapine and Quetiapine versus Risperi‐
done, Aripiprazole, and Haloperidolum in reducing the anxiety symptoms in pa‐
tients diagnosed with schizophrenia and schizoaffective disorder hospitalized in
the Psychiatry Department of Arad between 2013–2014.
Considering the treatment, 63 subjects were divided in two groups: T1 (treated with
Olanzapine and Quetiapine) and T2 (treated with Haloperidolum, Risperidone, and
Aripiprazol).
Anxiety is frequent in the course of schizophrenia and schizoaffective disorder with
significant differences among the two groups. After treatment, the level of anxiety
reduced with significant improvement of total score of PANSS; the effect is higher
in group T2 compared to T1. Before treatment, anxiety is positively correlated with
scores of PANSSN (r=.285; p=0.010), PANSST (r=.260; p=0.040), and HAM-D (r=.455;
p<0.0001).YMRS is negatively correlated with negative items of PANSSN scale (r=-.
321; p=0.010). IQ (intelligence quotient) was decreased posttreatment for both treat‐
ments, but T1 had had a higher effect on it.
Some antipsychotics have been reported to be successful in reducing the anxiety
level in psychotic patients: in group T2 the treatment has a higher effect on anxiety
and lower size effect on intelligence.
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1. Introduction
Anxiety disorders are serious, debilitating conditions, with wide discrepancies being found in
the reports of the prevalence rates, in clinical and epidemiological studies.
Based on the literature, the rate of prevalence of anxiety disorder in patients with schizophrenia
or schizoaffective disorder remains uncertain due to limiting factors: the definitions of the
disorders themselves the sample size, the study procedures and the utilization of different
measures and clinical assessments.
A meta-analysis by Achim et al., in 2011, found a prevalence rate for anxiety disorder of 38.3%
in the schizophrenic population, compared with 28.8% reported for the general population [1].
Seedat et al., in 2007, in a study of hospitalized schizophrenic patients, found that 25% suffered
from anxiety disorder [2]. In 2007, using a sample of inpatients, Ciapparelli et al. found anxiety
disorders in 74% of the subjects [3].
In a study conducted by Braga et al., in 2004, 42% of schizophrenic outpatients presented
anxiety disorders [4].
In schizoaffective disorder, the rates of anxiety disorders range from 32% in outpatients [3] to
45% in inpatients [5].
Schizophrenia is a common, chronic and severe mental illness defined by the presence of
delusions, hallucinations, and disorganized behavior (positive symptoms); by the presence of
apathy, social withdrawal, and involution (negative symptoms); and by cognitive disorgani‐
zation [6].
It has long been known that anxiety has an important role in the psychopathology of schizo‐
phrenia. However, the nature of the development of anxiety disorder in psychosis is not well
understood.
The presence of the comorbidity of anxiety in major psychotic disorders (schizophrenia, schizo-
affective disorder) results in reduced cognitive functioning, increases the severity of comorbid
medical conditions, increases the risk of reoccurrence, adds to internalized stigma, reduces
functioning, and has a negative impact on the overall outcome for the patient.
Comorbid anxiety in schizophrenia and schizoaffective disorder is associated with the more
positive symptoms: extrapyramidal symptoms suggesting more severe medication side effects
[6], an increase in drug/alcohol abuse, a worsening of social and professional functioning, and
in the quality of life [7].
Anxiety is common among patients with schizophrenia or schizoafective disorder, and it may
also manifest itself as a symptom during an acute psychotic episode [8], as a result of the side
effects of medication or as a symptom of a comorbid anxiety disorder. Patients are generally
discharged as soon as their psychotic episode is resolved, with little recognition of the presence
of an anxiety disorder [9].
It is difficult to evaluate the relation of anxiety to psychotic symptoms since it is not clear which
anxiety symptoms the disorder is associated with. Furthermore, the operational criteria
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developed for the assessment of the level of anxiety found in the nonpsychotic population
(Hamilton Anxiety Rating Scale, Yale Brown Obsession Compulsion Rating) may themselves
be problematic. Extrapyramidal symptoms which develop secondary to neuroleptic treatment
may coincide with anxiety symptoms [7].
Progress in understanding the etiology of comorbid anxiety in major psychotic disorders such
as schizophrenia or schizoaffective disorder has been made. For example, in the field of
genetics, two basic genetic strategies have been developed, enabling a better understanding
of the etiology of anxiety: the linkage approach and the polymorphism or susceptibility allele,
which associates different genes (e.g., dysbindin, the gene for the dystrobrevin-binding protein
1, located within the linkage peak on chromosome 6 p; or chromosomal regions, e.g., 6p22.3)
with traits or illness [10].
Generally, anxiety disorders are relatively responsive to treatment so greater awareness should
be paid to their comorbidity with psychosis in order to obtain clinical benefits.
Comorbid anxiety may have implications for treatment choice. Generally, anxiety is consid‐
ered to be secondary to the psychotic condition and it is expected to improve simultaneous
with an improvement in the schizophrenic symptoms. There is some evidence that antipsy‐
chotic medication (such as Quetiapine) has some degree of efficacy in reducing anxiety in
schizophrenic patients [11].
The treatment for acute schizophrenia involves one of the newer generation antipsychotic
drugs which is well-tolerated and can be used for maintenance therapy. In particular, it is
desirable to use drugs with little sedative effect in order to optimize functioning and to
preserve the quality of life [12,13]. However, lack of compliance with antipsychotics must be
taken in consideration as it is known that nonadherence plays a significant role in psychotic
relapse. In these cases, long-acting injectable antipsychotics (administered at two to four week
intervals) are preferable as they may result in a lower risk of dose-related adverse effects
(because of lower peak antipsychotic plasma levels) and lower rates of hospitalization due to
acute exacerbations. These factors contribute to improving the individual quality of life.
A personalized treatment approach is necessary in the management of comorbid anxiety with
schizophrenia which should be based on the pathogeneses and the clinical assessments.
In clinical practice, in those patients with significant agitation and anxiety, drugs with low
sedative potential are not sufficient for the reduction of these symptoms. In these patients,
anxiety may interfere with compliance to medication. So, benzodiazepines or sedative
neuroleptics (levomepromazine) are often incorporated into the antipsychotic treatment [13].
In practice, two strategies are available to satisfactorily manage the severe anxiety associated
with acute psychotic episodes: the use of sedative antipsychotic drugs (thioridazine, pipam‐
perone, melperone, cyamemazine, a-flupenthixol, and levomepromazine) [14, 15, 16] or the
use of adjuvant benzodiazepines therapy [17, 18, 19]. These sedative antipsychotics have been
shown to have anxiolytic effects at low doses both in nonpsychotic patients and during acute
psychotic episodes [18].
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In order to prevent the risk of benzodiazepine dependence and rebound anxiety on the
cessation of treatment, the use of benzodiazepines should be for as short a period as possible.
Benzodiazepines should be prescribed in combination with nonsedative disinhibitory atypical
antipsychotics.
Benzodiazepines used in psychotic episodes are drugs with potent anxiolytic action, a low
propensity for pharmacokinetic drug interactions, and a long half-life to ensure uninterrupted
cover [19, 20].
After the patient reaches a position where the symptoms are well-controlled, the treatment
can be switched to a nonsedative antipsychotic for maintenance therapy.
Some atypical antipsychotics rely on the serotonin (5-HT) neurotransmitter system. The
antagonism of 5-HT receptors permits the atypical antipsychotics to have a lower propensity
to cause extrapyramidal symptoms and tardive dyskinesia.
The 5-HT actions may also result in improvements in the negative or cognitive symptoms of
schizophrenia.
It has been proposed that the antagonism of 5-HT receptors and/or partial antagonism of 5-
HT receptors and antihistaminic properties may play a role in the antianxiety effect of some
atypical antipsychotics.
The literature indicates that Olanzapine and Quetiapine have a degree of efficacy in reducing
anxiety in schizophrenic and schizoaffective patients [11, 19].
In order to explore the efficacy of atypical antipsychotics in reducing comorbid anxiety in
schizophrenic and schizoaffective patients, we performed a study in our clinic.
We aimed to measure the efficacy of various antipsychotics in reducing anxiety levels in
patients diagnosed with schizophrenia and schizoaffective disorder, who had been hospital‐
ized in Arad between 2013-2014.
2. Methodology
2.1. Objectives
The aims of this study are: (a) to determine the relationship between anxiety and schizophre‐
nia/ schizoaffective disorder, (b) to determine if the anxiety level is reduced under pharma‐
cological treatment and to compare the efficacy in the two groups (T1- Olanzapine, Quetiapine;
and T2- Haloperidolum, Risperidone, Aripiprazol), and (c) to estimate the effect of antipsy‐
chotic treatment on cognitive ability (intelligence level, IQ).
2.2. Sample
Sixty three patients diagnosed with schizophrenia, schizoaffective disorder, and anxiety were
evaluated on admission and after 28 days of antipsychotic treatment. The patients were
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hospitalized in the Psychiatry Ward of The County Clinical Emergency Hospital in Arad,
between 2013–2014. The patients were divided in two groups: T1, who receieved anthypsi‐
chotic treatment with Olanzapine or Quetiapine; and group T2, who received treatment with
typical and atypical antipsychotics (Haloperidolum, Risperidone, and Aripiprazol).
The diagnoses of schizophrenia, schizoaffective disorder and anxiety disorders were estab‐
lished according to the ICD-1021[and DSM-V-TM22] criteria.
GENDER Females:54% Mean: 43.27
AGE Mean:43.27 SD: 7.5
EDUCATION Secondary school: 9% High school:
33.3%
Professional school:
46%
University:
7%
MARITAL STATUSNever married:
7.9%
Married:
20.6%
Divorced:
20.6%
In a relationship:
7.9%
ALCHOL USE 6.3%
Table 1. Sample characteristics
The sample (Table 1) presented the following socio-demographic characteristics: (a) gender:
54% females, 46% males; (b) age: mean = 43.27, SD = 7.5; (c) education: 9% secondary school,
33.3% high school, 46% professional school and 7% university; (d) marital status: 7.9% never
married, 20.6% married, 20.6% divorced, and 7.9% in a relationship; and (e) 6.3% alcohol use.
2.3. Measures
All subjects were evaluated using the following measures:
a. The Hamilton Anxiety Scale (HAM-A; Hamilton, 1959) [23] is a rating scale used to
quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by
a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present)
to 4 (severe).
b. Positive and Negative Syndrome Scale (PANSS; Kay SR, Fiszbein A, Opler LA. 1987) [24]
is a semistructured clinical interview scale comprising 30 items and a seven point severity
rating. There are seven psychiatric parameters belonging to a positive symptoms subscale,
seven parameters belonging to a negative symptoms subscale and 16 parameters belong‐
ing to a general psychopathology subscale. The interitem correlations for PANSS were
significant with a Cronbach's alpha between.71 to.83.
c. The Hamilton Depression Rating Scale (HAMD - 17 items; Hamilton M. A Rating Scale
for Depression 1960) [25] is a scale that measures the symptoms of depression experienced
over the previous week, and was originally developed for hospital inpatients. One
limitation of the HAMD is that atypical symptoms of depression (e.g., hypersomnia,
hyperphagia) are not assessed. A score of 0–7 is generally accepted to be within the normal
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range (or in clinical remission), while a score of 20 or higher (indicating at least moderate
severity) is usually required for entry into a clinical trial. HAMD have good internal
consistency, between 0.77 to 0.91.
d. YoungMania Rating Scale (YMRS) [26] is a rating scale used to evaluate manic symptoms
in individuals with mania. The scale has 11 items and is based on the patient’s subjective
report of his or her clinical condition over the previous 48 hours. The studies regarding
the psychometric characteristics of YMRS report a high degree of internal consistency (α
= 0.91).
e. Raven's Progressive Matrices [27] is a nonverbal multiple choice measure of general
intelligence; in each test item, the subject is asked to identify the missing element that
completes a pattern. On the Romanian sample of 2755 subjects, RPM reported a high
internal consistency (α =.91).
2.4. Procedure and design
The participants of this study filled in the tests package presented at the section work instru‐
ments. For the protection of the participants, they only noted a code on the answer papers. We
shall use the variance analysis (ANOVA factorial) considering that we shall observe the
simultaneous influence of two interdependent variables on the dependent variable.
We have structured our research into three studies as follows:
a. a correlation study—for which we have used Pearson correlation "r," in order to establish
the relationship between all measurements in the pretreatment phase.
b. a comparative study—between pre- and postintervention, respectively, between the two
treatments on the dependent variables (anxiety, mania, depression, and positive versus
negative psychotic symptoms); we have calculated ANOVA 2 x 2 - General Lineal Model
for Repeated Measurements for the cases in which there was no initial (pretreatment)
difference between the dependent variables means (e.g., HAMA, YMRS, PANSS-N).
ANOVA 2 x 2 as a statistical indicator is helpful to observe as well the evolution in time, as
well the effect on the dependent variables of the interaction between treatment condition and
evolution in time as independent variables.
We have calculated ANCOVA - General Lineal Model Univariate Analysis of Variance for
the cases in which we have observed an initial difference between the dependent variables
means (e.g., PANSS-P, PANSS-G, PANSS-T, HAMD).
ANCOVA as a statistic indicator helps to eliminate the initial difference (preintervention) from
the end-results (postintervention) in order to see if at the end the difference is significant as a
result of intervention and to estimate which would be the end-results means if we wouldn't
had initial differences.
c. a comparative study—on effect of the treatment on IQ as a dependent variable, for this
propose we have used ANCOVA - Univariate Analysis of Variance, because we have
observed a initial difference between the two groups regarding the IQ level.
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3. Results
3.1. Correlations
Before treatment, anxiety is positively correlated with the total score of negative items on the
PANSS scale (PANSSN: r =.285; p = 0.010); anxiety is also positively correlated with the total
score on PANSS (PANSST: r =.260; p = 0.040) and the total score for depression assessed
according to the Hamilton Depression Scale (HAM-D: r =.455; p<0.0001).
The score on the YMRS is negatively correlated with negative items on the PANSSN scale (r =
-.321; p = 0.010). In general, it is to be expected that a subject with negative symptoms will have
a lower level of mania.
The IQ was positive correlated with the total score on the PANSS scale (PANSST: r =.261; p =
0.036) suggesting, in our study, that a higher level of intelligence represents possible a risk in
the development of psychotic symptoms. The observed positive correlation between PANSST
and IQ accounts for approximately 9% of the variation.
Pearson IQ PANSSP PANSSN PANSSG PANSST HAMA YMRS HAMD No.Relapse Age
IQ
initial 1 .044 .162 .233 .261
* .108 -.015 .241 -.035 -.003
PANSS-P 1 .272* -.052 .403** .114 -.018 .053 .055 .082
PANSS-N 1 .174 .688** .057 -.321* .217 .286* .352**
PANSS-G 1 .769** .285* .003 .304* .027 .062
PANSS-T 1 .260* -.155 .332** .171 .242
HAMA 1 .001 .455** .133 .240
Sample N 63 63 63 63 63 63 63 63 63 63
PANSS-P = positive items of PANSS scale; PANSS-N = negative items of PANSS scale; PANNS-G = general items of
PANSS scale; PANSS-T = total score of PANSS scale; HAMA = Hamilton anxiety scale; YMRS = Young Mania Rating scale;
HAMD = Hamilton Depression scale; *. Significant at the 0.05 level (2-tailed). **. Significant at the 0.01 level (2-tailed).
Table 2. Preintervention correlations between all measurements
Based on these results, there is a possibility that IQ can be a risk factor in 9% of the cases to
stimulate the productivity of psychotic symptoms. Given this fact, we need to exercise a degree
of caution with regard to the afore mentioned conclusion.
3.2. Comparing treatments
To assess the level of the anxiety disorders in both groups before and after 28 days of antipsy‐
chotic treatment, we used an ANOVA 2 x 2 design.
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Because we expected that there would be initial differences between the two groups (T1 and
T2), we also performed a t-test for independent samples (table 2) for the pretreatment values,
in order to eliminate, if necessary, any initial differences from the postintervention results by
calculating ANCOVA in such cases.
We obtained statistically significant difference for the PANSS-P, PANSS-G, PANSS-T, and
HAM-D. To compare the efficacy of the treatment for these dependent variables between the
two groups we used ANCOVA.
Pre-intervention
measurments
t-test for Equality of Means
.t. df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference
95% Confidence
Interval of the
Difference
Lower Upper
PANSS-P Equal variances
assumed
-2.800 61 .007 -1.8589 .6638 -3.1862 -.5315
PANSS-N Equal variances
assumed
.578 61 .566 .6310 1.0926 -1.5538 2.8159
PANSS-G Equal variances
assumed
4.302 61 .000 6.1028 1.4187 3.2659 8.9397
PANSS-T Equal variances
assumed
2.206 61 .031 4.8468 2.1966 .4543 9.2392
HAMA Equal variances
assumed
1.025 61 .310 1.2319 1.2023 -1.1723 3.6360
YOUNG
MANIA
Equal variances
assumed
.181 61 .857 .3992 2.2024 -4.0047 4.8031
HAMD Equal variances
assumed
3.208 61 .002 3.4980 1.0903 1.3179 5.6781
PANSS-P = positive items of PANSS scale; PANSS-N = negative items of PANSS scale; PANNS-G = general items of
PANSS scale; PANSS-T = total items of PANSS scale; HAMA = Hamilton anxiety rating scale; YMRS = Young Mania
Rating SCALE; HAMD = hamilton depression rating scale;
Table 3. Preintervention differences between the two groups (in order to see if it is necessary to use ANCOVA
As the main goal of this study was to evaluate the efficacy of antipsychotic treatment for
anxiety, we compared the level of anxiety pre and postintervention, by using ANOVA because
there were no initial differences observed (see table 3).
Results showed that there were differences in the level of anxiety reduction between the two
groups: in group T2, the efficacy of the treatment was significantly higher than that of group
T1. The result obtained was confirmed by the t-test for independent samples applied postin‐
tervention at T1 and T2 (t = 3.018; p =.004).
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General Lineal Model – for Repeated Measurements for Anxiety
Source Sum of Squares df Mean Square F Sig.
Time (pre – post) 574.777 1 574.777 211.821 .000
Time * Treatments
(T1 vs T2) 22.904 1 22.904 8.441 .005
Error (Time) 165.524 61 2.714
Table 4. Comparing the level of anxiety pre and postintervention and between groups
The difference in anxiety reduction between the two groups (see table 4) was also measured,
by comparing T2 with T1 with Cohen’s D = 0, 7583; r = 0.3545.
Using the t-test for paired samples t (T1) = -4.901, p<0.0001 and t (T2) = -9.043, p<0.001, the
results obtained in our preliminary study revealed that both types of treatments are effective
in significantly reducing the intensity of anxiety both for schizophrenic and schizoaffective
patients.
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Figure 1. Pretreatment and posttreatment level of anxiety for both groups T1 (TS1 and TA1) and T2 (TS2 and TA2)
For both groups(Figure1), the results showed that with regard to the efficacy of the treatments
for the patients diagnosed with schizoaffective disorder compared to schizophrenic patients,
there was no difference, t (T1) = -3.94, p = 0.697 and t (T2) = 0.212, p = 0.933.
3.3. Comparing IQ
To eliminate the initial preintervention IQ differences between groups (t=5,162; p<.0001) we
applied ANCOVA. In both groups of patients, antipsychotic treatment has a negative effect
on cognitive functioning reducing IQ level,  but the cognitive dysfunction was higher in
group T1.
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Figure 2. Evolution of the IQ levels in T1 and T2 group
The results obtained showed that in posttreatment (Figure 2) there were no statistically
significant differences between the two groups, ANCOVA F = 1.085, p = 0.302. A possible
explanation for these results is that the T1 treatment had a greater effect on cognitive func‐
tioning when compared with the T2 treatment, so that even if the T2 group initially had a lower
intelligence level, after 28 days the difference was no longer significant (see Table 5).
Dependent Variable: IQ in evolution
Pre-Post Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
T1 treatment 74.07a .93 72.21 75.93
T2 treatment 75.551 .91 73.72 77.37
Note: a.Covariates appearing in the model are evaluated at the following values: IQ initial = 82.048.
Table 5. Estimated marginal means after eliminating the covariance of the Initial IQ
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4. Discussions and conclusions
The study’s results proved that preintervention anxiety is positively correlated with the total
score on PANSSN (r =.285; p = 0.010) and PANSST (r = 0.260; p = 0.040) and the total score on
HAM-D (r = 0.455; p<0.0001). Also the score on the YMRS is negatively correlated with the
negative items on the PANSSN scale (r = -0.321; p = 0.010). Our results are corroborated by
international studies [28, 29].
Based on the results of our study, the efficacy of Olanzapine or Quetiapine is lower than that
of the typical and other atypical antipsychotics (such as Haloperidolum, Risperidone, Aripi‐
prazol). Olanzapine or Quetiapine have a greater negative effect on cognitive functioning than
other antipsychotics.
These results are contrary to the international findings [11, 19, 30, 31].
In a study by Riedl et al., 2007 [19], both Quetiapine and Olanzapine improved cognition;
however, the improvement in cognitive index scores was more marked in patients receiving
Quetiapine. Quetiapine produce a significantly better improvement in reaction quality/
attention than Olanzapine [11, 19].
Olanzapine, an atypical antipsychotic, has proved to be efficient in reducing the positive and
negative symptoms of schizophrenia. Compared with conventional antipsychotics, it has
greater affinity for serotonin 5-HT2A than for dopamine D2 receptors. In large, well-controlled
trials involving patients diagnosed with schizophrenia, Olanzapine (5 to 20 mg/day) was
superior to Haloperidol (5 to 20 mg/day) in the treatment of depressive and negative symp‐
toms, comparable with effects on positive psychotic symptoms [28]. Contrary to these findings,
in our study patients treated with haloperidol, Risperidone, and Aripiprazol (group T2)
showed a greater reduction of symptomatology.
The 1-year risk of relapse of rehospitalisation was significantly lower with Olanzapine than
with Haloperidol treatment [35].
In the first double-blind comparative study [28, 29, 33]) of Olanzapine 10 to 20 mg/day and
Risperidone 4 to 12 mg/day, Olanzapine proved to be significantly more effective than
Risperidone in the treatment of negative and depressive symptoms but not for overall
psychopathological symptoms.
In contrast, preliminary results from an 8-week controlled study [34] suggested that Risperi‐
done 2 to 6 mg/day was superior to Olanzapine 5 to 20 mg/day in the treatment of positive
and anxiety/depressive symptoms, and that both agents demonstrated similar efficacy on
overall psychopathology. These results are similar to our findings (Risperidone was superior
to Olanzapine in reducing anxiety symptoms as confirmed by t-test for independent samples
applied postintervention at T1 and T2: t = 3.018; p = 0.004).
However, preliminary results from an 8-week trial showed comparable cognitive enhancing
effects for Olanzapine and Risperidone in patients with schizophrenia or schizoaffective
disorder [30]. In our study, in both groups of patients, (T1, T2), antipsychotic treatment has a
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negative effect on cognition with a larger effect on group T1 treated with Olanzapine and
Quetiapine.
Olanzapine demonstrated superior antipsychotic efficacy when compared to Haloperidol in
the treatment of acute phase schizophrenia, and in the treatment of some patients with first-
episode or treatment-resistant schizophrenia [35].
The reduced risk of adverse events and the therapeutic superiority, compared with Haloper‐
idol and Risperidone, in the treatment of negative and depressive symptoms support the
choice of Olanzapine as a first-line option in the management of schizophrenia in the acute
and maintenance phase of treatment response [36].
Aripiprazole, a 5-H1A partial agonist was found to have a considerable antianxiety effect
which may concur with procognitive and mood-ameliorating effects [32, 37, 38]. These are
similar to our results: when comparing T2 with T1 using effect size based on differences
between means (Cohen’s D = 0.7583; r = 0.3545), Aripiprazol is superior to Olanzapine and
Quetiapine in reducing anxiety in schizophrenic and schizoaffective disorder patients.
Regarding the cognitive dysfunction, posttreatment, in both groups of patients, we noticed a
negative effect on cognition, although there was no statistically significant differences between
the groups as determined by analysis of covariance (ANOVA F = 1.085; p = 0.302).
One hypothesis could be that this agonism of Aripiprazole is a mechanism contributing to
antianxiety effects. Case reports and studies on the antipsychotic augmentation by Aripipra‐
zole in partial responders to Clozapine found a considerable antianxiety effect [32].
However, this could be due to external factors or to the natural evolution of the illness. A
randomized controlled study is required to evaluate the efficacy of the Clozapine-Aripiprazole
combination in cases of treatment-resistant schizophrenia with a predominance of anxiety [39].
Risperidone’s antianxiety action was demonstrated in the study by Blider et al. in 2002 [30],
conducted on 62 patients hospitalized for acute exacerbations of schizophrenia, randomly
assigned to receive Risperidone (a mean dose, 7.4 mg/day), Haloperidol (7.6 mg/day), or
Methotrimeprazine (100 mg/day) for 4 weeks. The antianxiety effects were significantly greater
in the Risperidone patients than the Methotrimeprazine patients. The difference between
Haloperidol and Methotrimeprazine was not significant.
It is concluded that Risperidone is an effective antipsychotic and anxiolytic agent in schizo‐
phrenic patients. These result are confirmed by our findings in group T2 (t = 3.018; p = 0.004).
New Drug Perspectives
It is generally agreed upon that anxiety is a frequently occurring symptom of schizophrenia,
strongly associated with an increased risk of relapse and more severe symptomatology. The
effects of antipsychotics in reducing anxiety in psychotic patients remain controversial and the
practice of prescribing adjuvants (benzodiazepines) is unsatisfactory [17, 18].
The next clinical trials for schizophrenia with comorbid anxiety perhaps will show the efficacy
of some new compounds (the anticonvulsant/anxiolytic pregabalin and the atypical antipsy‐
chotic Quetiapine) [40].
A Fresh Look at Anxiety Disorders142
Consequently, we think there is a need for more research in order to obtain a clear perspective
of the efficacy of Olanzapine or Quetiapine. It should also be pointed out that our findings
suffer from certain limitations: such as (a) the lack of a control group, (b) the small sample size,
(c) the short treatment time, and (d) the lack of a follow-up evaluation after three and six
months, and after one year. Our results can serve as a guide to future studies regarding the
efficacy of psychopharmacological treatment on comorbid anxiety.
Limitations
The methodological limitations of this study will be addressed in a follow-up study: this was
a preliminary study with a small sample size, lacking follow up evaluations at 3 months, 6
months and 1 year. Given that some of these patients will be inevitably lost to the follow up,
a large sample size will need to be used in order to ensure that sufficient numbers are available
to obtain meaningful repeat measures.
Acknowledgements
This paper is partly supported by the Sectorial Operational Programme Human Resources
Development (SOPHRD), financed by the European Social Fund and the Romanian Govern‐
ment under contract number POSDRU 141531.
Author details
Delia M. Podea1*, Aurora I. Sabau1 and Karol J. Wild1
*Address all correspondence to: deliapodea@yahoo.com
1 “Vasile Goldis” Western University of Arad, County ClinicalEmergency Hospital of Arad,
Psychiatry Department, Arad, Romania
“Vasile Goldis” Western University of Arad, Psychology Department, Arad, Romania
References
[1] Achim A. M., Maziade M., Raymound E., Olivier D., Merette C., Roy M.A.: How
prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review
on a significant association. Schizophrenia Bulletin, 2011, 37:811-821.
[2] Seedat S., Fritelli V., Oosthuizen P., Emsley R. A., Stein D. J.: Measuring anxiety in
patients with schizophrenia. Journal of Nervous Mental Disease. 2007; 1995 : 320-324.
Comorbid Anxiety in Schizophrenia and Schizoaffective Disorder
http://dx.doi.org/10.5772/60643
143
[3] Ciapparelli A., Paggini R., Marazitti D., Carmassi C., Bianchi M., Taponecco C., Con‐
soli G., Lombardi V., Massimetti G., Dell’Osso L.: Comorbidity with axis 1 anxiety
disorders in remitted psychotic patients 1 year after hospitalization. CNNS Spectr
2007; 12:913-919.
[4] Braga R. J., Petrides G., Figuueira I.: Anxiety disorders in schizophrenia. Compr Psy‐
chiatry 2004; 45:460-468.
[5] Cosoff S.J., Hafner R.J.: The prevalence of comorbid anxiety in schizophrenia, schizo‐
afective disorder and bipolar disorder. Aust NZJ Psychiatry 1998;32:67-72.
[6] American Psychiatric Association: The Diagnostic and Statistical Manual of Mental
Disorders, 5th edition, Washington, DC. 2013.
[7] Tibbo P., Swainson J., Chue P., LeMelledo J.M.: Prevalence and relationship to delu‐
sion and hallucinations of anxiety disorders in schizophrenia. Depress Anxiety
2003;17:65-72. DOI:10.1002/da.10083.
[8] Argyle N., et al.: Panic attacks in chronic schizophrenia. Br J Psychiatry 1990;430–
433.DOI: 10.1192/bjp.157.3.430.
[9] Blanchard Jack J., Mueser Kim T., Bellack Alan S.: Anhedonia, positive and negative
affect, and social functioning in schizophrenia. Schizophrenia Bulletin
1998;24.3:413-424.
[10] Schwab S.G., Albus M., Hallmayer J., Honig S., Borrmann M., Lichtermann D., Eb‐
stein R.P., Ackenheil M., Lerer B., Risch N., Maier W., Wildenauer D.B.: Evaluation of
a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib‐
pair linkage analysis. Nature Genetics. 1995; 11:325-327.doi:10.1038/ng1195-325.
[11] Cutler Andrew J., Quetiapine, Evidence in reducing Anxiety: Clinical Evidence may
suggest the atypical antipsychotic (quetiapine fumarate) tablets, is effective in reduc‐
ing anxiety in patients with schizophrenia. Presented at the American Psychiatric As‐
sociation annual meeting, May 5 - 10 2001; New Orleans, Louisiana 2001.
[12] Garay RP., d’Alche-Birée, Cyamémazine F.: Profil neuroleptique ou anxiolytique?
L’Information Psychiatrique Lille 1995;71: 969-971.
[13] Goodwin R.D., Amador X.F., Malaspina D., Yale S.A., Goetz R.R., Gorman J.M.:
Anxiety and substance use comorbidity among inpatients with schizophrenia. Schiz‐
ophr Res 2003 May 1; 61(1): 89-95.
[14] Squelart P., Saravia J.: Pipamperone (Dipiperon), a useful sedative neuroleptic drug
in troublesome chronic psychotic patients. Acta Psychiatr Belg. 1977;77:284-293.
[15] Meltzer H.Y., Sumiyoshi T., Jayathilake K.: Melperone in the treatment of neurolep‐
tic-resistant schizophrenia. Psychiatry Res. 2001;105:201-209.
[16] Poldinger W. J.: Melperone in low doses in anxious neurotic patients. A double-blind
placebo-controlled clinical study. Neuropsychobiology. 1984;11:181-186.
A Fresh Look at Anxiety Disorders144
[17] Barbee J.G., Mancuso D.M., Freed C.R., Todorov A.A.: Alprazolam as a neuroleptic
adjunct in the emergency treatment of schizophrenia. Am J Psychiatry
1992;149:506-510.
[18] Wolkowitz O.M., Pickar D.: Benzodiazepines in the treatment of schizophrenia: a re‐
view and reappraisal. Am J Psychiatry. 1991;148:714-726.
[19] Riedel M, Muller N, Spellmann I, Engel RR.: Efficacy of Olanzapine versus Quetia‐
pine on cognitive dysfunction in patients with an acute episode of schizophrenia.
Arch. Psychiatry Clin Neurosa 2007;402-412.
[20] Lingjaerde O.: Benzodiazepines in the treatment of schizophrenia: an updated sur‐
vey. Acta Psychiatr Scand. 1991;84:453-459.
[21] World Health Organization: The ICD-10 classification of mental and behavioural dis‐
orders: Clinical descriptions and diagnostic guidelines. 1992. Geneva: World Health
Organization.
[22] American Psychiatric Association: Diagnostic and statistical manual of mental disor‐
ders (4th ed., text rev.). Washington, DC: APA.2000.
[23] Hamilton M.: The assessment of anxiety states by rating. Br. J Med Psychol
195932:50-55.
[24] Kay S.R., Fiszbein A., Opler L.A.: The positive and negative syndrome scale (PANSS)
for schizophrenia. Schizophrenia Bulletin 1987 ;13261-275.
[25] Hamilton M.: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;
Hamilton Depression Rating Scale (HDRS).
[26] Young R.C., Biggs J.T., Ziegler V. E., Meyer D. A.: Young Mania Rating Scale. In:
Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Associa‐
tion; 2000: 540-542.
[27] Raven J.: Raven's Progressive Matrices. Journal of Psychoeducational Assessment
1998; 17,354-361. doi: 10.1177/0013164498058003002.
[28] Bhana N., Foster R.H., Olney R.: Olanzapine: an updated review of its use in the
management of schizophrenia. Drugs 2011;61(1):111-161.
[29] Gao K., Muzina D., Gajwani P., Calabrese J. P.: Efficacy of typical and atypical anti‐
psychotics for primary and comorbid anxiety symptoms or disorders: a review. Jour‐
nal of Clinical Psychiatry 2006 ;67(9):1327–1340.
[30] Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., Linden‐
mayer J.P., Citrome L., McEvoy J., Kunz M., Chakos M., Cooper T.B., Horowitz T.L.,
Lieberman J.A.: Neurocognitive effects of Clozapine, Olanzapine, Risperidone, and
Haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am.
J. Psychiatry2002;159:1018–1028.
Comorbid Anxiety in Schizophrenia and Schizoaffective Disorder
http://dx.doi.org/10.5772/60643
145
[31] Schirmbeck F., Esslinger C., Rausch F., Englisch S., Meyer-Lindenberg A., Zink M.:
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms
in schizophrenia. Psychol Med 2011;41(11):236.
[32] Chanachev A. et al.: Case Reports in Psychiatry Volume 2011. Article ID 846489, 3 pa‐
ges.
[33] Moore N. A., Tye N.C., Axton M.S., Risius F.C.: The behavioral pharmacology of
Olanzapine, a novel “atypical” antipsychotic agent. Journal of Pharmacology and Ex‐
perimental Therapeutics1992; 262(2): 545–551.
[34] Kim S.W., Shin I.S., Kim J.M., Youn T., Yang S.J., Hwang M.Y., Yoon J.S.S.O.: The 5-
HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive
symptoms in schizophrenia. Clin Neuropharmacol 2009; 32(4):224.
[35] Csernansky J.G., Schuchart E.K.: Relapse and rehospitalisation rates in patients with
schizophrenia: effects of second generation antipsychotics. CNS Drugs2002;16:473–
484.
[36] TollefsonG.D., Sanger T.M., Lieberman J.A.: Olanzapine versus Haloperidol in the
treatment of first episode psychosis. Schizophrenia Research 1997; 24.doi:
10.4103/2279-042X.128142
[37] Paton C., Whittington C., Barnes T.R.: Augmentation with a second antipsychotic in
patients with schizophrenia who partially respond to Clozapine. a meta analysis. J
Clin Psychopharmacol 2007; 27:198-204.
[38] Swainston Harrison T., Perry C.M.: Aripiprazole: a review of its use in schizophrenia
and schizoaffective disorder Drugs 2004;64(15):1715-1736.
[39] Karunakaran K., Tungaraza T.E., Harborn G.C.: Is Clozapine-Aripiprazole combina‐
tion a useful regime in the management of treatment-resistant schizophrenia? Jour‐
nal of Psychopharmacology 2007; 21(4):453–456. doi: 10.1093/schbul/sbn018.
[40] Garay R.P., Samalin L., Hameg A., Llorca P. M.: Investigational drugs for anxiety in
patients with schizophrenia. [Internet]. 2014, November 25. Available from http://
informahealthcare.com/doi/abs/10.1517/13543784.2014.987339.[Accesed:2014-12-20].
A Fresh Look at Anxiety Disorders146
